Xcout Intel
SpliSense
SpliSense is an Israeli biotechnology company developing antisense oligonucleotide therapies that correct disease-causing RNA splicing defects. Its programs are aimed at patients with genetic diseases, including specific mutations associated with cystic fibrosis.
Subscribe to see SpliSense’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
SpliSense at a glance
SpliSense is a biotechnology company headquartered in Israel, founded in 2016. It has raised at least $41.5M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $13M in June 2026. Xcout tracks 8 named people at SpliSense, including Gili Hart (CEO).
SpliSense leadership
- Gili HartCEO
- Lior BuchmanCEO at Integra Holdings
- Batsheva KeremChief Scientist
- Dr. Nissim DarvishChairman, Venture Partner at Orbimed & Managing General Partner at MeOhr Ventures
- Dr. Stanley FielRegional Chairman of Medicine at Atlantic Health
- Ido ZairiGeneral Partner at Israel Biotech Fund
2 more named people on record for SpliSense, with roles, board committees and tenure — see the full roster →
SpliSense funding rounds
At least $41.5M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $13M | 4 named | |
| Series B | $28.5M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
SpliSense competitors
A few of SpliSense's closest competitors — see the full list of competitors and alternatives →
Skip Therapeutics is an Israeli biotechnology company founded in 2021 and based in Ness Ziona. The company develops personalized RNA-based therapies, including antisense oligonucleotides, for rare genetic disorders and common diseases using a proprietary computational discovery engine.
SpliceBio is a clinical-stage genetic medicines company that develops gene therapies using a proprietary Protein Splicing platform. The company focuses on treating diseases caused by mutations in large genes, with a lead clinical program targeting Stargardt disease.
Sionna Therapeutics is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, focused on developing treatments for cystic fibrosis.
Averna Therapeutics is a biotechnology company developing genomic medicines utilizing RNA and lipid nanoparticle technologies. The company focuses on safe and efficient gene insertion and the treatment of rare genetic diseases through research and development teams located in Boston and Israel.
Rznomics is a South Korean biotechnology company developing RNA-based gene therapies using a trans-splicing ribozyme platform. Its programs are focused primarily on therapeutic applications in cancer and other serious diseases, serving patients through prospective drug-development and clinical partnerships.
Dynacure is a biotechnology company developing antisense oligonucleotide therapies for rare neuromuscular diseases. Its lead program, DYN101, targets DNM2-associated centronuclear myopathy for patients with this serious inherited muscle disorder.
Get SpliSense's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on SpliSense in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access